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Dear Editor,
The treatment of post-neurosurgical meningitis,
ventriculitis, or central nervous system (CNS) shunt infections
is a difficult clinical problem and is associated with a high
morbimortality rate [5]. The widespread use of antibiotics
led to the emergence of Gram-negative bacteria on these in-
fections [2].
In adults, there are numerous reported methods for the
treatment of CNS shunts infections, although no randomized,
prospective studies have ever been performed [6]. In pediatric
patients, there are only a few case reports in the literature. We
report two cases of pediatric neurosurgical patients and the
clinical data are summarized in Table 1.
A 15-month-old boy, submitted to ventricular-peritoneal
shunt (VPS) valve replacement 1 month before, with
Escherichia coli and Klebsiella pneumoniae, both extended
spectrumβ-lactamases (ESBL) isolated on cerebrospinal fluid
(CSF) cultures. On the eighth day of meropenem, after VPS
removal, CSF cultures remained positive; an 11-month-old
boy with hydrocephalus secondary to neonatal group B strep-
tococcal meningitis was brought to the hospital 16 days after
VPS placement and Acinetobacter baumannii was identified
in CSF culture. After 6 days of meropenem and amikacin,
CSF cultures remained positive.
Since our patients did not improve after adequate intrave-
nous antibiotic therapy, we considered the administration of
colistin, an old class of cationic, cyclic polypeptide antibiotic.
Colistin CSF penetration after intravenous administration ap-
pears to be minimal and, although it increases with meningitis,
the concentrations achieved may be inadequate [1]. Therefore
we considered intraventricular administration.
There is a dose discrepancy recommended to intraventric-
ular use in the reviewed studies. In children the daily dose
range from 2000 IU/kg (0.16 mg/kg) up to 125,000 IU
(10 mg) [4]. For our 15- and 11 month-old patients, we decid-
ed to dilute colistin with preservative-free NaCl 0.9 % to a
concentration of 2 mg/ml and extrapolated the dose to admin-
ister based among all the published cases in children: on the
first day, a single dose of 1 mg, 2 mg on the second day
followed by 4 mg continued 10 days in patient 1 and 9 days
on patient 2. The direct instillation of colistin was achieved
through external ventricular devices after the removal of a
greater or equal volume of CSF used for daily cultures and
cytochemistry, in a mean speed of 0.5 ml/min. Whenever a
higher volume of CSF was removed, normosaline sterile so-
lution was instilled. The catheter was closed for at least 1 h.
The decision to stop should be based on the clinical and
microbiological response but we consider that a 10-day period
after the first CSF-negative culture is a safe option considering
the antimicrobial properties of colistin and the risk for toxicity.
Both patients were submitted to simultaneous intraventric-
ular colistin administration and intravenous therapy with a
different antimicrobial class, reported susceptible.
Removal of all components of the infected shunt in com-
bination with appropriate antimicrobial therapy is the most
effective treatment for CNS shunt infections. Success rates
are lower when the shunt is treated in situ because of the
ability of many of these microorganisms to adhere to prosthe-
ses and survive antimicrobial therapy [6] through the
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production of biofilm. None of the strains identified on our
patients were tested for their ability to form a biofilm.
The exact time to remove the infected catheter should be
discussed with the neurosurgical team and it should be con-
sidered after the first negative CSF culture [3]. If, as it hap-
pened in our patients, is necessary a drainage catheter because
of the hydrocephalus an external drain should be placed until
the infection is cleared.
The most significant adverse effect related to intraven-
tricular instillation of colistin is reversible chemical
ventriculitis and meningitis. It presents as a bacterial men-
ingitis with sterile CSF cultures [3]. Seizures were noted
in both patients and anticonvulsants were prescribed with
control of symptoms. These episodes were not related to
colistin instillation because they happened before the be-
ginning of the topical administration. They were probably
secondary to valve dysfunction.
Successful clinical and bacteriological outcome was
achieved in both with follow-up time of 17 and 16 months
after hospital discharge.
Direct instillation of colistin in the CNS is safe and suitable
for treating nosocomial infections by Gram-negative bacteria
especially in patients suffering shunt infections difficult to
eradicate and/or those unable to undergo surgery to remove
the device [6].
We emphasize the lack of guidelines regarding the ideal
management in children and further studies of the appropriate
colistin pediatric dosage are still required.
The patients’ guardians have consented to the submission
of the case report for submission to the journal.
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Meropenem 0.75 μl/ml 14 2
11 Hydrocephalus VPS Acinetobacter
baumannii
Meropenem, amikacin <0.5 μl/ml 13 2
VPS ventriculoperitoneal shunt, ESBL extended spectrum β-lactamases, MIC minimum inhibitory concentration, CSF cerebrospinal fluid
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